Sector News

GSK CEO says looking at Pfizer consumer business, but not a priority

January 10, 2018
Life sciences

GlaxoSmithKline’s new chief executive said on Tuesday that the British drugmaker would have a look at Pfizer Inc’s  consumer products business, but would not overpay for the asset.

Pfizer, the largest U.S. drugmaker, said last year it was considering strategic alternatives, including a sale or spinoff, of the consumer business, which had sales of about $3.4 billion in 2016 and could cost more than $15 billion to acquire.

“At this stage it would be weird if we didn’t look at it,” GSK Chief Executive Emma Walmsley said, responding to questions at the JP Morgan Healthcare Conference in San Francisco.

But she said it is only a look and very early, adding, “we don’t need it and we won’t overpay for it.”

Despite her consumer products background, Walmsley repeatedly said that the company’s pharmaceuticals business and pharma research and development is GSK’s top priority.

However, Walmsley said GSK has a good track record of integrating large acquisitions and that it’s consumer business does have room to grow.

Pfizer’s consumer portfolio includes well-known brands such as Advil, Chapstick lip balm and Centrum vitamins.

Walmsley said there are a very small number of assets that would be completely complementary to GSK’s existing consumer business, “and this may be one of them.”

“If we did it, it is cash generating,” she said.

By Bill Berkrot

Source: Reuters

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).